Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 11/20 | 0.41 |
| ▸ | PPARA | Q07869 | 3/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | RARA | P10276 | 1/20 | 0.35 |
| ▸ | RARB | P10826 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.34 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29306133 | 0.99 | ACACB (0.39) | ACACBPPARAPPARGCYP2C9CYP1A2 | |
| SCHEMBL29306134 | 0.96 | ACACB (0.38) | ACACBPPARAPPARGCYP2C9CYP1A2 | |
| SCHEMBL23333349 | 0.96 | ACACB (0.40) | ACACBPPARAPPARGCYP2C9CYP1A2 | |
| SCHEMBL29306142 | 0.95 | MEN1 (0.39) | ACACBPPARAPPARGCYP2C9CYP1A2 | |
| SCHEMBL29306143 | 0.94 | LMNA (0.38) | ACACBPPARAPPARGCYP2C9CYP1A2 | |
| SCHEMBL29306138 | 0.94 | ACACB (0.39) | ACACBPPARAPPARGCYP2C9CYP1A2 | |
| SCHEMBL29306132 | 0.93 | MEN1 (0.39) | ACACBCYP1A2 | |
| SCHEMBL29306137 | 0.93 | ACACB (0.43) | ACACBPPARACYP2C9CHRNA7CHRNA10 | |
| SCHEMBL29306139 | 0.92 | ACACB (0.38) | ACACBPPARACYP2C9CYP1A2CYP19A1 | |
| SCHEMBL23333351 | 0.91 | APP (0.36) | ACACBPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228878-A1 | COMPOUND, LIQUID CRYSTAL COMPOSITION, AS WELL AS LIQUID CRYSTAL DISPLAY ELEMENT, SENSOR, LIQUID CRYSTAL LENS, OPTICAL COMMUNICATION EQUIPMENT, AND ANTENNA EACH USING THE SAME | DIC CORPORATION (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20240228878-A1 | COMPOUND, LIQUID CRYSTAL COMPOSITION, AS WELL AS LIQUID CRYSTAL DISPLAY ELEMENT, SENSOR, LIQUID CRYSTAL LENS, OPTICAL COMMUNICATION EQUIPMENT, AND ANTENNA EACH USING THE SAME | DIC CORPORATION (JP) | 2024-07-11 | — | — | US | disclosed |
| WO-2021085280-A1 | LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL ELEMENT, SENSOR, LIQUID CRYSTAL LENS, OPTICAL COMMUNICATION DEVICE, AND ANTENNA | DIC株式会社 | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228878-A1 | COMPOUND, LIQUID CRYSTAL COMPOSITION, AS WELL AS LIQUID CRYSTAL DISPLAY ELEMENT, SENSOR, LIQUID CRYSTAL LENS, OPTICAL COMMUNICATION EQUIPMENT, AND ANTENNA EACH USING THE SAME | TTI2, CCT4, CCT2 | ACACB 1767/4885PPARA 3873/4885PPARG 3163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.